Pharmacophore generation by FieldTemplater
In FieldTemplater 9 , 500 low energy ligand conformations were used for the conformational search of the template molecules. Parameters such as the maximum number of conformations were set to 500, the number of high-T dynamics runs for flexible rings was set to 10, the gradient cutoff for conformer minimization was set to 0.30 kcal/mol/Å, and the RMS value to filter duplicate conformers was set to 0.50 Å. For template building, the minimum number of molecules per template was set to 2, the maximum number of comparisons per pair was set to 200, the maximum score delta per pair was set to 0.1, the minimum link density in a template was set to 0.8, and duplicate templates were filtered at 0.7 Å. For the conformational search, yielding an optimal alignment to the template, the score fraction from the shape similarity was set to 0.5, a weighted average score method was used for multiple reference. No field constrains were applied for building the template. For representing electrostatic and van der Waals properties of ligands (figure 2A), field points 10 were derived using the XED 3 force field by calculating the Coulombic interaction between probe atoms such as a charged oxygen atom for positive (red) and negative field points (cyan). A neutral oxygen atom was used as probe for calculating the Morse potential term for van der Waals interactions (yellow). Neutral oxygen atoms were also used to calculate the attractive energy term for hydrophobic field points (orange) by assigning zero weights to the electronegative atoms. The size of the field points in figure 2A corresponds to the magnitude of the interaction energy. This employs molecular field based similarity methods for conformational search to design a pharmacophore template which resembles the bioactive conformation. The two compounds used for the pharmacophore template generation were KL001 (PDB crystal structure 4MLP) and KL044 docked into the crystal structure of CRY protein bound to KL001. The pharmacophore was obtained by the conformational search of KL001 and KL044 in FieldTemplater 9 , which resembles their respective bioactive conformation in CRY protein. In the pharmacophore template based on low energy conformations of KL001 and KL044, the values for 2D-similarity, field similarity and shape similarity were 0.763, 0.699 and 0.827, respectively. As previously shown, in the case of Cholecystokinin 2 Receptor Antagonists 11 and novel reversible Cdc25 inhibitors 12 , ligand field point profiles for structurally different ligands were related to their binding capability in the protein. Hence, ligand fields essential for binding could be elucidated and used for virtual screening.
3D-QSAR based on the field points
The pharmacophore template obtained from the FieldTemplater 9 was directly transferred into the Forge 9 software, where the compounds were aligned to the template. Field point based descriptors were used for building 3D-QSAR model after the alignment of 60 compounds on to the pharmacophore template. For building the 3D-QSAR model, the maximum number of components was set to 20, the sample point maximum distance was set to 1.0 Å, Y scrambles were set to 50, and Electrostatic as well as Volume fields were used. For overall similarity, Forge uses 50% Field similarity and 50% Dice volume similarity. The overlays with the best matching low energy conformation to the template were taken into consideration for building the 3D-QSAR model. Linear correlation between similarity and field similarity with the experimental pEC 50 s were obtained from the alignment of the compounds to the pharmacophore template as shown in figure S2A and S2B. This provided a good starting point for building a 3D-QSAR model.
Generation of prediction set and field pattern contribution to the predicted activity
Design principal for KL065 is described in the main text and figure 3B, and that for KL066, KL067, KL068, and KL069 is described below. Their activities are listed in table S1. To obtain a compound with favorable sterics, mesyl group in KL034 was modified to carbonyl tbutyl in KL066 to have better activity as shown by cyan cubes in figure S4A . Other substitutions such as phenyl moiety in KL037 and cyclo-propane in KL036 increase the unfavorable sterics (purple cubes). To study whether the hydrogen bond of -OH with S394 can be replaced with halogen interaction, -OH moiety in KL001 was modified to di-fluoro moiety in KL067, which resulted in lowering of the activity. The replacement of mesyl group with octanal (KL068) or 3-cyclopropyl-1H-pyrazole (KL069) also resulted in the lowering of the activity indicating the importance of CH-π interactions with W290 and W397. The bulkier replacements of mesyl moiety were sterically hindered. Based on the field pattern contribution to the predicted activity, figure S4B shows the evolution of medicinal chemistry for ortho substituent at benzyl moiety that supports the benefit of ortho modification indicated in figure 4A . When the -F moiety (KL047) is substituted to -CF 3 (KL048) or -I (KL043) moiety, the activity increases due to the improved electrostatics (cyan cubes) while increasing the unfavorable sterics (purple cubes).
C. Chemical synthesis
General. All chemicals and solvents were obtained from commercial suppliers (Acros and Aldrich) and used without further purification. Unless otherwise indicated, all reactions were run under argon gas. Anhydrous solvents were purchased from Acros chemical company. 1 H and 13 C NMR spectra were recorded on a Bruker 400 MHz spectrometer. Chemical shifts are reported relative to internal CDCl 3 (Me 4 Si, δ 0.0) and CD 3 CN (Me 4 Si, δ 0.0). All compounds were identified by LC-MS from Agilent Technology, using a C 18 column (20  4.0 mm), with 20 minutes elution using a gradient solution of CH 3 CN-H 2 O (containing 0.05% trifluoroacetic acid), with UV detector and an electrospray ionization source.
General procedure of the synthesis of compound 3. Scheme S1. The scheme of a synthesis of compound 3.
The synthesis of N-(furan-2-ylmethyl)methanesulfonamide (1).
A solution of furfuyl amine (500 mg, 5.15 mmol) in pyridine (4 mL) was treated with methansulforyl chloride (500 uL, 6.17 mmol). The reaction mixture was stirred for 24h at room temperature. The reaction mixture was diluted with CH 2 Cl 2 , washed with 5% HCl solution, and brine. The organic layer was dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure. The crude compound was purified by flash column chromatography (CH 2 Cl 2 :Hexane=1:1) to give a grey color solid (767.6 mg, 85.3%)
The synthesis of N-(furan-2-ylmethyl)-N-(oxiran-2-ylmethyl)methanesulfonamide (2). A solution of compound 1 (500 mg, 2.85mmol) in DMF (10 mL) was treated with NaH (85 mg, 3.42mmol, 1. The synthesis of compounds (3). A solution of carbazole (50 mg, 0.21mmol) in DMF (3 mL) was treated with NaH (11 mg, 0.42mmol, 2.0 equiv) and stirred for 30min at room temperature, followed by compound 2 (48 mg, 0.2 mmol) in DMF (2 mL). The reaction mixture was stirred for 2 hrs at 60 o C. The reaction mixture was diluted with ethyl acetate, washed with 5% HCl, and brine. The crude material was purified by flash column chromatography to give compounds. 
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General procedure for the synthesis of compound 7.
Scheme S2. The scheme of the synthesis of compound 7.
We followed the previous procedure 1 for the synthesis of compound 5. A solution of 1-(9H-carbazol-9-yl)-3-((furan-2-ylmethyl)amino)propan-2-ol (5) (50 mg, 0.16mmol) in THF (2 mL) was treated with DIEA (20 mg, 0.16mmol, 25 mL) and followed acyl chloride (0.16 mmol). After stirring at room temperature overnight, the reaction mixture was extracted with ethyl acetate (50 mL) and water (20 mL). Organic layer was dried with MgSO 4 . The organic layer was evaporated under reduced pressure. Crude compound was purified by Prep-HPLC with 0.05 % trifluoroacetic acid-water/0.05 % trifluoroacetic acid-acetonitrile to afford compound. General procedure for the synthesis of compound 10.
Scheme S3. The scheme of the synthesis of compound 10.
We followed the previous procedure for the synthesis of compound 9. A solution of carbazole (250 mg, 1.5mmol) in DMF (5 mL) was treated with NaH (41 mg, 1.7mmol, 1.2 equiv) and stirred for 30min at room temperature, followed by compound 9 (242 mg, 0.85mmol) in DMF (2 mL). The reaction mixture was stirred for 2 hrs at 60 o C. The reaction mixture was diluted with ethyl acetate, washed with 5% HCl, and brine. The crude material was purified by flash column chromatography to give compounds.
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1 H-NMR (CDCl 3 -d 32 (m, 3H), 3.55-3.51 (m, 2H), 3.49 (s, 1H), 3.47-3.42 (m, 2H), 3.38-3.32 (m, 2H) Method A: A solution of compound 11 (100 mg, 1.1mmol) in DMF (5 mL) was treated with chloroacetyl chloride (102 L, 1.2 mmol). The reaction mixture was stirred at RT overnight. If starting material remained, the reaction mixture was stirred at 40 o C overnight. Method B: A solution of compound 11 (100 mg, 1.1mmol) in CH 2 Cl 2 (10mL) was treated with TEA (162 L, 1.2mmol, 1.2 equv.) and chloroacetyl chloride (102 L, 1.2 mmol). The reaction mixture was stirred at room temperature overnight. After reaction complete, the reaction mixture was purified by flash column chromatography (ethyl acetate:hexan=1:3) to give compound 12.
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A solution of carbazole (20 mg, 0.12 mmol) in DMF (3 mL) was treated with NaH (6 mg, 0.24mmol, 2.0 equiv.). The reaction mixture was stirred at room temperature for 1hr and followed by compound 12 (20 mg, 0.12 mmol, 1.0 equiv.) in DMF (2mL). The reaction was stirred at 60 o C overnight. The reaction mixture was diluted with ethyl acetate (20mL) and wash with water. The organic layer was dried with Na 2 SO 4 , filtered, concentrated under reduce pressure. Crude material was purified by flash column chromatography (ethyl aceate:hexane=1:2) to give compound 13. Table   Table S1 . The structure of training set (black), test set (blue), and prediction set (red) compounds with experimental and predicted activities. NA: not active. substituent at ortho benzyl moiety in KL044 series based on the contribution of the field points to the predicted activity in 3D-QSAR. Experimental pEC 50 s are given in the brackets. Color code for field points contributions: favorable electrostatic (green), unfavorable electrostatic (orange), favorable steric (cyan), and unfavorable steric (purple).
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